Fibrosis is a condition where the body's natural process of forming scars for wound healing goes into overdrive and causes diseases. The new findings, published in the advance online Nov. 10 issue of
, demonstrate a potential novel therapeutic approach to treat fibrotic diseases such as idiopathic pulmonary fibrosis and liver fibrosis.
The research targets a pathway that turns off the trigger for the major molecular mediator of fibrosis, a protein called Transforming Growth Factor (TGF) beta. This protein is normally present in the body in an inactive state and must be turned on to cause fibrosis. Once activated, TGF beta protein stimulates cells called myofibroblasts to produce excess collagen, which is a principle component of scars.
The researchers showed that removing a gene in the myofibroblasts that makes a specific subset of proteins called alpha v integrins blocks the ability of these cells to trigger activation of TGF beta. Furthermore, they were able to replicate the effect of the gene deletion by treatment with a small molecule compound, thus opening the door to a potential new therapy for patients.
"This is the first foray into targeting not just a single integrin, but rather several integrins that appear to be working in concert to promote fibrosis," said David Griggs, Ph.D., Director of Biology at Saint Louis University's Center for World Health and Medicine and an author of the paper.
"We have developed small molecular compounds that selectively inhibit these integrins, which suppress TGF beta protein, and these have been effective in animal models of lung and liver fibrosis."
The small molecule was not only able to prevent fibrosis; it made fibrosis less severe even when the treatment was started after fibrosis had begun, Griggs added.
"It's really a platform technology that could be applied to a number of fibrotic conditions," Griggs said.
In tandem with the drug discovery research, scientists working on another part of the study found they could protect mice from pulmonary fibrosis, liver fibrosis and renal fibrosis by deleting a gene that makes the same specific integrins in myofibroblasts that were targeted by the drug.
"We want to hit the integrins that are linked to fibrosis, but leave integrins that are not involved in fibrosis alone," said Peter Ruminski, Executive Director of Saint Louis University's Center for World Health and Medicine and an author of the paper. "We're trying to bring TGF beta levels back to normal."
Fibrosis, which can occur in any of the body's organs, can contribute to deadly diseases by preventing organs from functioning properly because the fibrotic tissue hardens and swells. For instance, there is no FDA-approved treatment for pulmonary fibrosis, which has a high mortality rate and affects up to 150,000 Americans. Because there are no available drug treatments for pulmonary fibrosis in the US, the only effective therapy is an organ transplant. However transplants are expensive and demand for organs exceeds the supply, creating the need for more effective therapies.
The next steps, Ruminski said, are to determine exactly how much of the compound is needed to allow normal healing to occur instead of fibrosis. Scientists also need to study the best way to deliver the drug. Different fibrotic conditions could warrant different delivery methods, Ruminski speculated. For instance, an inhaled delivery method could be better to treat pulmonary fibrosis or a topical cream could be preferable for skin scarring, he said.
The lead author on the paper is Neil Henderson, MBChB., Ph.D., University of Edinburgh, who conducted his research at UC San Francisco; the senior author is Dean Sheppard, M.D., Ph.D., also at UCSF.
Other authors are Yoshio Katamura, Ph.D., Marilyn M. Giacomini, Ph.D., Juan D. Rodriguez, Thomas D. Arnold, M.D., Jacquelyn J. Maher, M.D., UC San Francisco; Joseph H. McCarty, Ph.D., University of Texas M.D. Anderson Cancer Center; Elisabeth Raschperger, Ph.D., and Christer Betsholtz, Ph.D., Karolinska Institutet, Stockholm, Sweden; Antonella Pellicoro, Ph.D., and Alison Mackinnon, Ph.D., John P. Iredale, M.D. , University of Edinburgh; Michael J. Prinsen, Saint Louis University's Center for World Health and Medicine; Adam Lacy-Hulbert, Ph.D., Massachusetts General Hospital and Harvard Medical School; and Ralf H. Adams, Ph.D., Max Planck Institute for Molecular Biomedicine at the University of MÃ¼nster, Germany.
Ruminski and Griggs are co-founders of Antegrin Therapeutics, LLC, a drug discovery and development company dedicated to commercializing novel integrin inhibitors for the treatment of fibrotic diseases. The first start-up that Saint Louis University has spun out of the Center for World Health and Medicine, Antegrin presently holds an exclusive option to license the intellectual property concerned and expects to complete shortly an exclusive global license with the University's Office of Technology Management. Antegrin's development activity builds on the scientific foundation published for the first time in Nature Medicine. Internationally recognized for his expertise, Sheppard is a scientific and medical advisor and key collaborator.
Antegrin is led by President & CEO Robert Karr, M.D. Initial investment for the launch of Antegrin was provided by the BioGenerator's i6 Project Fund, which is supported by the U.S. Department of Commerce's Economic Development Administration, in partnership with the National Institutes of Health and the National Science Foundation. Antegrin has also received funding from the Missouri Technology Corporation.
Saint Louis University's Center for World Health and Medicine is dedicated to the discovery and development of safe, effective and affordable therapies for neglected diseases that primarily threaten impoverished children in the developing world. It evaluates promising drug candidates to find medical solutions to debilitating and life-threatening global health problems and rare and orphan diseases that pharmaceutical companies typically don't explore.